Larvol Veri

No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	PTC596 Sensitive: B - Late Trials PTC596 Sensitive : B
Chr amplification(4)(q22.1) Chr amplification(4)(q22.1)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(3)(q14.2) Chr del(3)(q14.2)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(11)(q25) Chr del(11)(q25)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(2)(q14.1) Chr del(2)(q14.1)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(2)(p12) Chr del(2)(p12)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
Chr del(1)(q44) Chr del(1)(q44)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(8)(q13.2) Chr amplification(8)(q13.2)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(8)(q22.2) Chr amplification(8)(q22.2)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(13)(q13.3) Chr amplification(13)(q13.3)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(20)(p12.2) Chr amplification(20)(p12.2)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(4)(q26) Chr amplification(4)(q26)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
ATRX mutation ATRX mutation	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
TP53 mutation TP53 mutation	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
ATRX mutation ATRX mutation	Leiomyosarcoma Leiomyosarcoma	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3
TP53 mutation TP53 mutation	Leiomyosarcoma Leiomyosarcoma	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3
PLK4 expression PLK4 expression	Leiomyosarcoma Leiomyosarcoma	CFI-400945 Sensitive: D – Preclinical CFI-400945 Sensitive : D
CSPG4 overexpression CSPG4 overexpression	Leiomyosarcoma Leiomyosarcoma	CSPG4.TNK Sensitive: D – Preclinical CSPG4.TNK Sensitive : D
HAT1 overexpression HAT1 overexpression	Leiomyosarcoma Leiomyosarcoma	pazopanib Resistant: D – Preclinical pazopanib Resistant : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES